丹芪通络胶囊联合双嘧达莫治疗冠心病心绞痛的效果观察

摘要/Abstract

摘要： 目的研究丹芪通络胶囊联合双嘧达莫治疗冠心病心绞痛的效果。方法选择2021年1月—2022年9月内江市中医医院收治的110例冠心病心绞痛患者,按随机数表法分为对照组和观察组,每组55例。对照组患者服用双嘧达莫治疗,观察组患者服用丹芪通络胶囊和双嘧达莫治疗,两组均治疗1个月。检测两组患者的血清脂蛋白相关磷脂酶A2（Lp-PLA2）、可溶性细胞间黏附分子-1（sICAM-1）、超敏C反应蛋白（hs-CRP）和单核细胞趋化蛋白-1（MCP-1）水平,且比较两组患者的全血黏度（WBV）、血小板黏附率（PAR）、纤维蛋白原（FIB）、血浆黏度（PV）和中医症状。结果观察组患者的有效率明显高于对照组,差异有统计学意义（P<0.05）;治疗1月后,两组患者的血清Lp-PLA2、sICAM-1、hs-CRP和MCP-1水平均明显降低（P<0.05）,且观察组的血清Lp-PLA2、sICAM-1、hs-CRP和MCP-1水平明显低于对照组（P<0.05）;治疗1月后,两组患者的WBV、PV、FIB和PAR均明显降低（P<0.05）,且观察组患者的WBV、PV、FIB和PAR明显低于对照组（P<0.05）;治疗1月后,两组患者的乏力倦怠、心胸疼痛、气短、心悸怔忡和胸闷积分均明显降低（P<0.05）,且观察组的乏力倦怠、心胸疼痛、气短、心悸怔忡和胸闷积分明显低于对照组（P<0.05）。结论双嘧达莫联合丹芪通络胶囊能明显改善冠心病心绞痛患者的血液流变学,减轻炎症反应和中医症状,提高疗效。

关键词: 双嘧达莫, 丹芪通络胶囊, 冠心病心绞痛

Abstract: Objective To investigate the effect of Danqitongluo capsule combined with dipyridamole on angina pectoris of coronary heart disease. Methods A total of 110 patients with coronary heart disease and angina pectoris admitted to Neijiang Hospital of Traditional Chinese Medicine from January 2021 to September 2022 were selected, and was divided into two groups according to the randomized number table method. The control group was treated with dipyridamole, and the observation group was treated with Danqitongluo capsule and dipyridamole. The levels of serum lipoprotein associated phospholipase A2 (Lp-PLA2), soluble intercellular adhesion molecule-1 (sICAM-1), hypersensitive C-reactive protein (hs-CRP) and monocyte chemoattractant protein-1 (MCP-1) were measured in the two groups, and the whole blood viscosity (WBV), platelet adhesion rate (PAR), fibrinogen (FIB), plasma viscosity (PV) and TCM symptoms were compared between the two groups. Results The response rate in the observed group was 96.36%, which was significantly higher than the 74.54% in the control group (P<0.05). After 1 month of treatment, the serum Lp-PLA2, sICAM-1, hs-CRP and MCP-1 levels in the two groups were significantly reduced (P<0.05), and the serum Lp-PLA2, sICAM-1, hs-CRP and MCP-1 levels in the observation group were significantly lower than those in the control group (P<0.05). After 1 month of treatment, WBV, PV, FIB and PAR in the two groups were significantly reduced (P<0.05), and WBV, PV, FIB and PAR in the observation group were significantly lower than those in the control group (P<0.05). After 1 month of treatment, the scores of fatigue, chest pain, shortness of breath, palpitation and chest distress in the two groups were significantly reduced (P<0.05), and the scores of fatigue, chest pain, shortness of breath, palpitation and chest distress in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Dipyridamole combined with Danqitongluo capsule can significantly improve the hemorheology of patients with coronary heart disease and angina pectoris, reduce inflammatory reaction and TCM symptoms, and improve the efficacy.

Key words: dipyridamole, Danqitongluo capsule, angina pectoris

中图分类号:

R541

何苗苗, 王畅. 丹芪通络胶囊联合双嘧达莫治疗冠心病心绞痛的效果观察[J]. 中华养生保健, 2023, 41(10): 22-25.

HE Miao-miao, WANG Chang. Effect of Danqitongluo Capsule Combined with Dipyridamole on Angina Pectoris of Coronary Heart Disease[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(10): 22-25.

参考文献

[1] 王培颖,闫奎坡,张奕颖.心悦胶囊联合非洛地平治疗冠心病心绞痛的疗效及对血清细胞因子的影响[J].现代药物与临床,2021,36(5):926-930.
[2] 柴娟娟,韩卫星,张松文.氯吡格雷联合依折麦布对冠心病心绞痛患者内皮功能及脂代谢的影响[J].中国临床药理学杂志,2021,37(1):12-15.
[3] 肖涛,张安武,程小娟,等.瓜蒌薤白半夏汤联合阿司匹林对冠心病心绞痛急性发作患者疗效及凝血功能的影响[J].中国中医急症,2022,31(3):483-485.
[4] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[5] 郑筱萸. 中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:85-89.
[6] 李兰霞,王东雁,王蒙,等.红景天注射液与芪苈强心胶囊对冠心病心绞痛患者抗氧化应激指标及心功能的影响[J].中国中西医结合急救杂志,2022,29(1):53-56.
[7] 白丽娜,张虹,严萍,等.心可舒治疗冠心病心绞痛的疗效及对血液流变学及炎症因子的影响——一项多中心,随机,双盲,安慰剂对照临床研究[J].实用药物与临床,2021,24(8):678-683.
[8] 靳小双,李金凤,岳亮,等.银杏酮酯滴丸联合替米沙坦治疗老年冠心病心绞痛疗效及对血清IL-33,sST2轴表达的影响[J].标记免疫分析与临床,2021,28(7):1175-1180,1184.
[9] 董正,张羽嘉,陈会君.加味丹参饮治疗冠心病心绞痛伴抑郁焦虑状态(气滞血瘀型)的临床随机对照试验[J].广州中医药大学学报,2021,38(7):1329-1334.
[10] 王彦,陈加容,安闵生,等.丹参多酚酸盐治疗老年冠心病心绞痛疗效及对血脂代谢,血流动力学和心肌谱酶水平的影响[J].中华中医药学刊,2021,39(2):199-202.
[11] 成冯镜茗,王连心,谢雁鸣.注射用丹参多酚酸盐与阿司匹林联用治疗冠心病心绞痛临床定位的四维度设计[J].世界中医药,2020,15(1):1-6,12.
[12] 张以昆,韩景波,王庆高,等.化痰开痹汤对冠心病心绞痛痰浊痹阻型病人血栓前状态及血小板聚集率的影响[J].中西医结合心脑血管病杂志,2022,20(10):1732-1735.
[13] 李国林,姜雪.冠脉宁通方治疗气虚痰瘀互结证冠心病心绞痛效果及对冠状动脉斑块的影响[J].现代中西医结合杂志,2020,29(4):85-88.
[14] 焦子贻,沈丹丹,李月,等.基于中医传承辅助平台分析治疗冠心病心绞痛中药复方的用药规律[J].天津中医药大学学报,2021,40(1):36-41.
[15] 白小平. 丹芪通络胶囊在改善急性ST段抬高型心肌梗死患者冠状动脉微循环障碍中的临床作用[J].心血管病防治知识:学术版,2018,15(4):36-37.
[16] 吴芸,周淑妮.冠心病不稳定型心绞痛患者中医证型分布及其与Gensini评分,炎症因子的关系[J].四川中医,2021,39(10):63-66.
[17] 王永,关宏弟,田丹丹.尼可地尔对冠心病介入治疗后心绞痛的疗效及对VEGF,sICAM-1,MMPs-9,炎症因子表达影响[J].贵州医药,2020,44(7):1052-1053.
[18] 刘爱菊,刘磊,冯肖亚,等.血清ICAM-1,hs-CRP及MCP-1与急性脑梗死病人颈动脉斑块性质的相关性[J].蚌埠医学院学报,2021,46(12):1751-1756.
[19] 王大刚. 丹参酮ⅡA磺酸钠和比索洛尔治疗冠心病心绞痛的效果及对血清PAI-1,Lp-PLA2的影响[J].河北医药,2020,42(5):1420-1422,1426.
[20] 范平,曹培镇,康兴霞,等.丹芪通脉胶囊治疗冠心病心绞痛气虚血瘀型115例临床观察[J].湖南中医杂志,2016,32(7):1-3.